中国防痨杂志:《中国结核病患者关怀手册》专家解读

2022-01-21 中国防痨杂志 中国防痨杂志

实施贯穿“防”“诊”“治”“管”“教”、全流程、全周期和全链条的患者关怀

为进一步减少结核病危害,全面提升各级结核病诊疗服务水平和质量,实施贯穿“防”“诊”“治”“管”“教”、全流程、全周期和全链条的患者关怀,中国疾病预防控制中心组织专家编写并出版印发了《中国结核病患者关怀手册》。该手册根据《国际结核病关怀标准》,并在结合近10年来我国结核病防治工作实践和相关政策、技术策略、新技术、新工具发展的基础上,进一步规范和细化了患者关怀的各项防控措施,具有较强的指导性和可操作性。笔者详细解读了其制定背景、主要内容和特点,以期促进各级各类医疗卫生机构规范结核病的诊断、治疗及管理,提高“以患者为中心”的服务质量和水平。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2132460, encodeId=8f6b213246073, content=看了看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41068580208, createdName=ms8000000988914972, createdTime=Thu May 11 22:09:14 CST 2023, time=2023-05-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1927438, encodeId=ffef192e438e5, content=<a href='/topic/show?id=590220681a0' target=_blank style='color:#2F92EE;'>#专家解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20681, encryptionId=590220681a0, topicName=专家解读)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Jun 19 03:26:06 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746227, encodeId=eed61e462277c, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 30 22:26:06 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254429, encodeId=d3d5125442942, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jan 23 00:26:06 CST 2022, time=2022-01-23, status=1, ipAttribution=)]
    2023-05-11 ms8000000988914972 来自海南省

    看了看了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2132460, encodeId=8f6b213246073, content=看了看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41068580208, createdName=ms8000000988914972, createdTime=Thu May 11 22:09:14 CST 2023, time=2023-05-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1927438, encodeId=ffef192e438e5, content=<a href='/topic/show?id=590220681a0' target=_blank style='color:#2F92EE;'>#专家解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20681, encryptionId=590220681a0, topicName=专家解读)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Jun 19 03:26:06 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746227, encodeId=eed61e462277c, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 30 22:26:06 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254429, encodeId=d3d5125442942, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jan 23 00:26:06 CST 2022, time=2022-01-23, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2132460, encodeId=8f6b213246073, content=看了看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41068580208, createdName=ms8000000988914972, createdTime=Thu May 11 22:09:14 CST 2023, time=2023-05-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1927438, encodeId=ffef192e438e5, content=<a href='/topic/show?id=590220681a0' target=_blank style='color:#2F92EE;'>#专家解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20681, encryptionId=590220681a0, topicName=专家解读)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Jun 19 03:26:06 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746227, encodeId=eed61e462277c, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 30 22:26:06 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254429, encodeId=d3d5125442942, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jan 23 00:26:06 CST 2022, time=2022-01-23, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=2132460, encodeId=8f6b213246073, content=看了看了, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=41068580208, createdName=ms8000000988914972, createdTime=Thu May 11 22:09:14 CST 2023, time=2023-05-11, status=1, ipAttribution=海南省), GetPortalCommentsPageByObjectIdResponse(id=1927438, encodeId=ffef192e438e5, content=<a href='/topic/show?id=590220681a0' target=_blank style='color:#2F92EE;'>#专家解读#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20681, encryptionId=590220681a0, topicName=专家解读)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=80c5136, createdName=drj2003, createdTime=Sun Jun 19 03:26:06 CST 2022, time=2022-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1746227, encodeId=eed61e462277c, content=<a href='/topic/show?id=6b49e865466' target=_blank style='color:#2F92EE;'>#结核病患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78654, encryptionId=6b49e865466, topicName=结核病患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Tue Aug 30 22:26:06 CST 2022, time=2022-08-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1254429, encodeId=d3d5125442942, content=<a href='/topic/show?id=f30ae86297d' target=_blank style='color:#2F92EE;'>#结核#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78629, encryptionId=f30ae86297d, topicName=结核)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4dfa37, createdName=huhuaidong387, createdTime=Sun Jan 23 00:26:06 CST 2022, time=2022-01-23, status=1, ipAttribution=)]

相关资讯

指南推荐《结核病患者接种新型冠状病毒疫苗的专家建议》

新型冠状病毒肺炎疫情仍在全球大范围流行,作为控制疫情的重要措施,新型冠状病毒疫苗接种正在全球范围内推广。结核病人群是新型冠状病毒感染和疾病重症化的高危人群,应优先考虑疫苗接种。

重磅: 《2021年全球结核病报告》发布 ------ 权威解读报告中的关键数据

2021年10月14日,世界卫生组织(WHO)发布了《2021年全球结核病报告》。

J Immunother Cancer:接受免疫检查点抑制剂治疗的癌症患者患肺结核的风险比普通人高 8 倍!

接受免疫检查点抑制剂治疗的癌症患者患肺结核的风险比普通人高 8 倍!

WHO报告: 新冠疫情让结核病终结的国际目标越来越遥不可及

2021年10月14日,世界卫生组织(WHO)发布了《2021年全球结核病报告》,为全球提供最新的、最全面的、最权威的结核病疫情评估,同时提供诊断、治疗和预防方面取得的最新进展。

结核病与COVID-19合并感染全球负担

TB可能是重度COVID-19的危险因素。